# Swedish guidelines

Anders Johnsson, MD, PhD
Dept of Oncology
Skåne University Hospital
Lund
Sweden

NOAC möte Oslo 1909

#### **Analcancer**

#### Nationellt vårdprogram

2017-12- 07 Version: 1.0





Uppdatering pågu

Tabell 4. Exempel på fraktioneringsscheman vid sekventiell strålbehandling respektive simultant integrerad boost (SIB). D=totaldos (Gy), d=fraktionsdos (Gy), n=antal fraktioner.

	Behandlingsschema A		Behandlingsschema B		Behandlingsschema C			
Stadium	T1N0M0 postop		T1-2 (< 4 cm) N0 M0		T2 (> 4 cm)-T4/N+M0			
Teknik Target	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB 1 D/n (d)	SIB 2 D/n (d)	
Primär-	44.0/22	44.0/22	54.0/27	54.0/27	58.0/29	58.0/29	57.5/27	
tumör	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.13)	
Lgl-met					58.0/29	58.0/29	57.5/27	
> 4 cm					(2.00)	(2.00)	(2.13)	
Lgl-met					50.0/25	51.0/29	50.5/27	
< 4 cm					(2.00)	(1.76)	(1.87)	
Adj Igl	40.0/20	40.7/22	40.0/20	41.6/27	40.0/20	42.1/29	41.6/27	
	(2.00)	(1.85)	(2.00)	(1.54)	(2.00)	(1.45)	(1.54)	
Cyto- statika	FUMIx1	1	FUMIx1	1	FUMIx2	1		

Tabell 4. Exempel på fraktioneringsscheman vid sekventiell strålbehandling respektive simultant integrerad boost (SIB). D=totaldos (Gy), d=fraktionsdos (Gy), n=antal fraktioner.

	Behandlingsschema A		Behandlingsschema B		Behandlingsschema C			
Stadium	T1N0M0 postop		T1-2 (< 4 cm) N0 M0		T2 (> 4 cm)-T4/N+M0			
Teknik Target	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB 1 D/n (d)	SIB 2 D/n (d)	
Primär-	44.0/22	44.0/22	54.0/27	54.0/27	58.0/29	58.0/29	57.5/27	
tumör	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.13)	
Lgl-met					58.0/29	58.0/29	57.5/27	
> 4 cm					(2.00)	(2.00)	(2.13)	
Lgl-met					50.0/25	51.0/29	50.5/27	
< 4 cm					(2.00)	(1.76)	(1.87)	
Adj Igl	40.0/20	40.7/22	40.0/20	41.6/27	40.0/20	42.1/29	41.6/27	
	(2.00)	(1.85)	(2.00)	(1.54)	(2.00)	(1.45)	(1.54)	
Cyto- statika	FUMIx1		FUMIx1	1	FUMIx2	1	1	

Sequential treatment "Shrinking fields"

Simultaneous Integrated Boost

Tabell 4. Exempel på fraktioneringsscheman vid sekventiell strålbehandling respektive simultant integrerad boost (SIB). D=totaldos (Gy), d=fraktionsdos (Gy), n=antal fraktioner.

	Behandling	gsschema A	Behandlin	gsschema B	Behandlingsschema C			
Stadium	T1N0M0 postop		T1-2 (< 4 cm) N0 M0		T2 (> 4 cm)-T4/N+M0			
Teknik Target	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB 1 D/n (d)	SIB 2 D/n (d)	
Primär-	44.0/22	44.0/22	54.0/27	54.0/27	58.0/29	58.0/29	57.5/27	
tumör	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.13)	
Lgl-met					58.0/29	58.0/29	57.5/27	
> 4 cm					(2.00)	(2.00)	(2.13)	
Lgl-met					50.0/25	51.0/29	50.5/27	
< 4 cm					(2.00)	(1.76)	(1.87)	
Adj Igl	40.0/20	40.7/22	40.0/20	41.6/27	40.0/20	42.1/29	41.6/27	
	(2.00)	(1.85)	(2.00)	(1.54)	(2.00)	(1.45)	(1.54)	
			ı	1	1	1	1	
Cyto- statika	FUMIx1		FUMIx1		FUMIx2			

Adjuvant treatment after primary surgery RO-R1 resection

Tabell 4. Exempel på fraktioneringsscheman vid sekventiell strålbehandling respektive simultant integrerad boost (SIB). D=totaldos (Gy), d=fraktionsdos (Gy), n=antal fraktioner.

	Behandlingsschema A		Behandlingsschema B		Behandlings			
Stadium	T1N0M0 postop		T1-2 (< 4 cm) N0 M0		T2 (> 4 cm)-T4/N+M0			
Teknik Target	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB 1 D/n (d)	SIB 2 D/n (d)	
Primär-	44.0/22	44.0/22	54.0/27	54.0/27	58.0/29	58.0/29	57.5/27	
tumör	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.13)	
Lgl-met					58.0/29	58.0/29	57.5/27	1
> 4 cm					(2.00)	(2.00)	(2.13)	
Lgl-met					50.0/25	51.0/29	50.5/27	
< 4 cm					(2.00)	(1.76)	(1.87)	
Adj Igl	40.0/20	40.7/22	40.0/20	41.6/27	40.0/20	42.1/29	41.6/27	
	(2.00)	(1.85)	(2.00)	(1.54)	(2.00)	(1.45)	(1.54)	
	ı	ı	·	·	1	ı	1	
Cyto- statika	FUMIx1		FUMIx1		FUMIx2		•	

Early tumors <4cm

More advanced tumors >4cm
T4
N+

Tabell 4. Exempel på fraktioneringsscheman vid sekventiell strålbehandling respektive simultant integrerad boost (SIB). D=totaldos (Gy), d=fraktionsdos (Gy), n=antal fraktioner.

	Behandlingsschema A		Behandlin	gsschema B	Behandlingsschema C			
Stadium	T1N0M0 postop		T1-2 (< 4 cm) N0 M0		T2 (> 4 cm)-T4/N+M0			
Teknik Target	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB 1 D/n (d)	SIB 2 D/n (d)	
Primär-	44.0/22	44.0/22	54.0/27	54.0/27	58.0/29	58.0/29	57.5/27	
tumör	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.13)	
Lgl-met					58.0/29	58.0/29	57.5/27	
> 4 cm					(2.00)	(2.00)	(2.13)	
Lgl-met					50.0/25	51.0/29	50.5/27	
< 4 cm					(2.00)	(1.76)	(1.87)	
Adj Igl	40.0/20	40.7/22	40.0/20	41.6/27	40.0/20	42.1/29	41.6/27	
	(2.00)	(1.85)	(2.00)	(1.54)	(2.00)	(1.45)	(1.54)	
			ı		ı	ı		
Cyto- statika	FUMIx1	•	FUMIx1	•	FUMIx2			

#### Compared to old guidelines:

Lower dose elective lymph node
 46 Gy — 40 Gy

Tabell 4. Exempel på fraktioneringsscheman vid sekventiell strålbehandling respektive simultant integrerad boost (SIB). D=totaldos (Gy), d=fraktionsdos (Gy), n=antal fraktioner.

	Behandlingsschema A		Behandlin	Behandlingsschema B		Behandlingsschema C			
Stadium	T1N0M0 postop		T1-2 (< 4 cm) N0 M0		T2 (> 4 cm)-T4/N+M0				
Teknik Target	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB D/n (d)	Sekv. D/n (d)	SIB 1 D/n (d)	SIB 2 D/n (d)		
Primär-	44.0/22	44.0/22	54.0/27	54.0/27	58.0/29	58.0/29	57.5/27		
tumör	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.00)	(2.13)		
Lgl-met					58.0/29	58.0/29	57.5/27		
> 4 cm					(2.00)	(2.00)	(2.13)		
Lgl-met					50.0/25	51.0/29	50.5/27		
< 4 cm				\	(2.00)	(1.76)	(1.87)		
Adj Igl	40.0/20	40.7/22	40.0/20	41.6/27	40.0/20	42.1/29	41.6/27		
	(2.00)	(1.85)	(2.00)	(1.54)	(2.00)	(1.45)	(1.54)		
Cyto- statika	FUMIx1		FUMIx1		FUMIx2				

#### Compared to old guidelines:

Lower dose to lymph node mets
 60 Gy — 50 Gy

#### National anal cancer board

- Every Friday
- All new cases and recurrence discussed
- Radiology reviewed and demonstrated
- TNM stage is settled
- Treatment recommendation
- Average 5-6 cases per week

